Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110266 · ClinicalTrials.gov registry record · Phase 2
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT00110266 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 176 participants.
The verdict
NCT00110266, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
Interventions
- DRUG Deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2005-07-25 |
| Est. Completion | 2008-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110266
The ClinicalTrials.gov registry entry for NCT00110266 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deferasirox is the first listed.
NCT00110266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110266 about?
NCT00110266 is a clinical study titled "Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients". The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
What is the current status of trial NCT00110266?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2005-07-25. Estimated completion is 2008-03-28.
What interventions are being tested in trial NCT00110266?
The interventions under investigation include: Deferasirox (DRUG).
Who is sponsoring clinical trial NCT00110266?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.